clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT04577404 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | Canada | Q16 |
Japan | Q17 | ||
United States of America | Q30 | ||
Italy | Q38 | ||
Germany | Q183 | ||
France | Q142 | ||
P582 | end time | 2023-09-01 | |
P1050 | medical condition | sclerosis | Q140067 |
amyotrophic lateral sclerosis | Q206901 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 140 | |
P4844 | research intervention | antioxidant | Q133948 |
edaravone | Q335099 | ||
mechanism of action | Q3271540 | ||
free radical scavengers | Q25401178 | ||
neuroprotective agent | Q50377190 | ||
P8005 | research subject recruitment status | active, not recruiting | Q76649790 |
P580 | start time | 2020-10-29 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS) |